p53 wild-typeOpinion statement:The treatment of endometrial cancer has recently undergone a paradigm shift from using traditional clinical-pathologic factors to molecular characterization for prognosis and selection of treatment. Recent approval of pembrolizumab, dostarlimab, and the combination of lenvatinib...
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma. J Clin Oncol 2023;41(16_suppl):TPS5627‑TPS56...
The four categories, similar to above TCGA classification in order of best to worst prognosis include 1) POLE, 2) p53 wild type, 3) Mismatch Repair deficient (MMRd), and 4) p53 abnormal (p53abn) (Kommoss et al., 2018). This molecular classification has been shown to correlate with ...
Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients withTP53wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers...
The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88, 814–824 (2000). Article CAS PubMed Google Scholar Wild, P. J. et al. p53 suppresses type II endometrial ...
Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1alpha/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic Biol Med. 2014;74:21–34. Article CAS PubMed Google Scholar Zhang HH, Guo XL. ...
p53-Wild-Type ICIs: Immune Checkpoint Inhibitor NA: Not Available EEC: Endometrioid Endometrial Carcinoma NEEC: Nonendometrioid Endometrial Carcinoma OS: Overall Survival PFS: Progression Free Survival DSS: Disease Specific Survival RFS: Relapse Free Survival FIGO: Federation International of...
Molecular subclassification of endometrial carcinoma (EC) with Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) identifies four subtypes [DNA polymerase epsilon (POLE) mutant, mismatch repair‐deficient, p53 wild‐type (wt), and p53 abnormal]. The aim of this study was to evaluate...
Interestingly, uterine serous carci- noma does not seem to be characteristic of the Li-Fraumeni syndrome in which patients with germline p53 mutations show a strong predisposi- tion to developing other types of cancer. Therefore, many factors other than p53 mutation must be involved in the ...
P53 wild-type tumors [56] are the most common subtype in young women and have been shown to respond better to progestin therapy [57]. Recent studies have indicated that patients with mismatch repair-deficient (MMRd) [58] status may have a higher risk of recurrence after initial regression ...